The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis

Respiratory Research

Volumn 14, Issue SUPPL. 1, 2013, Pages

  Cottin, Vincent ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

clinical trial; forced vital capacity; Idiopathic pulmonary fibrosis; pirfenidone

Indexed keywords

PIRFENIDONE; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; MORTALITY; MULTICENTER STUDY (TOPIC); NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SKIN DISEASE; SYSTEMATIC REVIEW; TREATMENT DURATION; ADVERSE DRUG REACTION; AGED; FEMALE; IDIOPATHIC PULMONARY FIBROSIS; MALE; PREVALENCE; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY; REVIEW;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; PREVALENCE; PYRIDONES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84876399666     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-14-S1-S5     Document Type: Article

References (31)

1. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174:810-816. 10.1164/rccm.200602-163OC, 16809633.
2. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002, 57:338-342. 10.1136/thorax.57.4.338, 1746288, 11923553.
3. Orphanet Orphanet Report Series. Rare Diseases collection. Prevalence of rare diseases: Bibliographic data. 2011, (Number 1). Orphanet., http://www.orphanet.net
4. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012, 21(126):355-61. 10.1183/09059180.00002512, 23204124.
5. Collard HR, King TE, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168(5):538-542. 10.1164/rccm.200211-1311OC, 12773325.
6. Kim DS, Collard HR, King TE. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006, 3(4):285-292. 10.1513/pats.200601-005TK, 2658683, 16738191.
7. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010, 35:496-504. 10.1183/09031936.00077309, 20190329.
8. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Care Med 2002, 165:277-304.
9. Nathan SD, du Bois RM. Idiopathic pulmonary fibrosis trials: recommendations for the jury. Eur Respir J 2011, 38:1002-1004. 10.1183/09031936.00068611, 22045786.
10. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011, 37:356-363. 10.1183/09031936.00159709, 20595144.
11. Valeyre D. Towards a better diagnosis of idiopathic pulmonary fibrosis. Eur Respir Rev 2011, 20:108-113. 10.1183/09059180.00001611, 21632798.
12. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011, 184(12):1382-9. 10.1164/rccm.201105-0840OC, 21940789.
13. Du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184:459-466. 10.1164/rccm.201011-1790OC, 21616999.
14. Richeldi L, Ryerson CJ, Lee JS, et al. Interstitial lung disease: Original article: Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012, 67:407-11. 10.1136/thoraxjnl-2011-201184, 22426899.
15. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003, 168:543-548. 10.1164/rccm.200209-1112OC, 12773329.
16. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824. 10.1164/rccm.2009-040GL, 21471066.
17. Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L. Hot of the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax 2012, 67(11):938-40. 10.1136/thoraxjnl-2012-202580, 23047830.
18. du Bois RM, Nathan SD, Richeldi L, Schwarz MI, Noble PW. Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med 2012, 86(8):712-5.
19. Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011, 20:85-97. 10.1183/09059180.00001111, 21632796.
20. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999, 291:367-373.
21. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999, 276:311-318.
22. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999, 289:211-218.
23. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008, 590:400-408. 10.1016/j.ejphar.2008.06.046, 18598692.
24. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respi Crit Care Med 2005, 171:1040-1047.
25. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35:821-829. 10.1183/09031936.00005209, 19996196.
26. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769. 10.1016/S0140-6736(11)60405-4, 21571362.
27. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Am J Respir Crit Care Med 1999, 159:1061-1069. 10.1164/ajrccm.159.4.9805017, 10194146.
28. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis (Review). Cochrane Database Syst Rev 2010, 9:CD003134.
29. Costabel U, Albera C, Cohen A, et al. The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Interim data from the RECAP extension study. Presented at The European Respiratory Society Annual Congress 2011 Abstract.
30. Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ. Idiopathic Pulmonary Fibrosis Clinical Research Network, Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012, 366(21):1968-77. 3422642, 22607134.
31. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011, 365:1079-1087. 10.1056/NEJMoa1103690, 21992121.